Identification of novel ATL biomarkers for stratifying onset risk and evaluation in clinical specimens

2023 Fiscal Year Final Research Report

• Project/Area Number: 21K06925
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 49020:Human pathology-related
• Research Institution: Oita University
• Principal Investigator: Iha Hidekatsu 大分大学, 医学部, 准教授 (50242631)
• Co-Investigator(Kenkyū-buntansha): 緒方 正男 大分大学, 医学部, 教授 (10332892) ; 萩原 將太郎 東京女子医科大学, 医学部, 非常勤講師 (50306635)
• Project Period (FY): 2021-04-01 – 2024-03-31
• Keywords: 成人T細胞白血病 / トランスクリプトーム / 発症リスク / 予後予測

Outline of Final Research Achievements

Twenty genes showing significant differences between ATL cells and Treg cells were identified through DNA microarray analysis of ATL cells. The top five genes (CADM1, Tex19, ID1, HoxB9, MEIS2) were evaluated as ATL biomarkers. CADM1 showed induction parallel to malignancy progression; ID1 and Tex19 exhibited constant expression across all malignant types; and HoxB9 and MEIS2 were expressed only in acute-type ATL, categorizing them into three groups. Inducible Tex19 and ID1 across all ATL subtypes suggest their role as ATL onset risk markers, while HoxB9 and MEIS2, limited to acute-type ATL, hint at their potential as prognostic markers for disease progression.

Free Research Field

分子腫瘍学

Academic Significance and Societal Importance of the Research Achievements

今回新たに特定した2つの異なるサブセットのATL新規バイオマーカーはATL発症リスクマーカーとして、または疾患進行の予後予測マーカーとなる可能性が示唆された。臨床標本を用いたさらなる研究が必要だが、定量的バイオマーカーの特定はATLの発症リスクを診断し、各患者に適切な治療オプションを提供する用途が期待される。